Io Biotech, Inc. IOBT
We take great care to ensure that the data presented and summarized in this overview for IO Biotech, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IOBT
View all-
Vivo Capital, LLC Palo Alto, CA6.17MShares$5.06 Million0.95% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA3.64MShares$2.98 Million2.22% of portfolio
-
Novo Holdings Hellerup, G73.35MShares$2.75 Million0.25% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA2.34MShares$1.92 Million0.14% of portfolio
-
Morgan Stanley New York, NY2.2MShares$1.81 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.11MShares$1.73 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC1.65MShares$1.35 Million0.0% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA864KShares$708,6410.71% of portfolio
-
Logos Global Management LP San Francisco, CA494KShares$404,9380.07% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX200KShares$163,6900.0% of portfolio
Latest Institutional Activity in IOBT
Top Purchases
Top Sells
About IOBT
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Insider Transactions at IOBT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 26
2024
|
Novo Holdings |
SELL
Open market or private sale
|
Direct |
23,478
-0.54%
|
$23,478
$1.31 P/Share
|
|
Jul 25
2024
|
Novo Holdings |
SELL
Open market or private sale
|
Direct |
51,522
-1.16%
|
$51,522
$1.33 P/Share
|
|
May 10
2024
|
Novo Holdings |
SELL
Open market or private sale
|
Direct |
658,809
-12.95%
|
$658,809
$1.22 P/Share
|
|
Feb 09
2024
|
Novo Holdings |
SELL
Open market or private sale
|
Direct |
658,809
-11.46%
|
$658,809
$1.5 P/Share
|
|
Nov 22
2023
|
Brian Burkavage Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+30.3%
|
$5,000
$1.03 P/Share
|
|
Nov 21
2023
|
Brian Burkavage Chief Accounting Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+43.48%
|
$0
$0.99 P/Share
|
|
Aug 09
2023
|
Christian E Elling |
BUY
Grant, award, or other acquisition
|
Indirect |
7,901,234
+36.16%
|
$7,901,234
$1.9 P/Share
|
|
Aug 09
2023
|
Invest A/S Lundbeckfond |
BUY
Grant, award, or other acquisition
|
Direct |
7,901,234
+36.16%
|
$7,901,234
$1.9 P/Share
|
|
Aug 09
2023
|
Novo Holdings |
BUY
Open market or private purchase
|
Direct |
2,469,135
+30.2%
|
$4,938,270
$2.02 P/Share
|
|
Aug 09
2023
|
Vivo Capital Ix, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,157,894
+50.0%
|
$3,157,894
$1.9 P/Share
|
|
Aug 09
2023
|
Amy Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,382
+39.9%
|
$49,382
$1.9 P/Share
|
|
Aug 09
2023
|
Mai Britt Zocca Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,037
+49.76%
|
$37,037
$1.9 P/Share
|
|
Aug 09
2023
|
Devin Whittemore Smith General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
4,938
+50.0%
|
$4,938
$1.9 P/Share
|
|
Mar 17
2023
|
Amy Sullivan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$50,000
$2.32 P/Share
|
|
Nov 09
2021
|
Jack Nielsen |
BUY
Open market or private purchase
|
Indirect |
650,000
+17.73%
|
$9,100,000
$14.0 P/Share
|
|
Nov 09
2021
|
Jack Nielsen |
BUY
Conversion of derivative security
|
Indirect |
2,365,545
+50.0%
|
-
|
|
Nov 09
2021
|
Invest A/S Lundbeckfond |
BUY
Open market or private purchase
|
Direct |
2,142,857
+26.16%
|
$29,999,998
$14.0 P/Share
|
|
Nov 09
2021
|
Invest A/S Lundbeckfond |
BUY
Conversion of derivative security
|
Direct |
3,906,595
+41.32%
|
-
|
|
Nov 09
2021
|
Mai Britt Zocca Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
26,580
+50.0%
|
-
|
|
Nov 09
2021
|
Claus A. Andersson |
BUY
Open market or private purchase
|
Indirect |
75,000
+4.02%
|
$1,050,000
$14.0 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 10K shares |
|---|
| Open market or private sale | 1.39M shares |
|---|